Description and references

Competitive histamine H₂-receptor antagonist which inhibits gastric acid secretion and reduces pepsin output. Prepn: G. J. Durant et al., BE 804144; eidem, US 3950333 (1974, 1976 both to SK&F); P. Kairisalo, E. Honkanen, Arch. Pharm. 316, 688 (1983). Chemistry, pharmacology and toxicology: R. W. Brimblecombe et al., J. Int. Med. Res. 3, 86 (1975); eidem, Br. J. Pharmacol. 53, 435p (1975). Use in combination with other drugs for cancer treatment: R. D. Thornes et al., Lancet 2, 328 (1982); S. Borgstr"om et al., N. Engl. J. Med. 307, 1080 (1982); 308, 591 (1983). Controlled clinical study in treatment of acute upper gastrointestinal tract bleeding: D. Barer et al., ibid. 1571; for prevention of recurrent duodenal ulcer: S. Sontag et al., ibid. 311, 689 (1984). Immunoregulatory effect: J. L. Jorizzo et al., Ann. Intern. Med. 92, 192 (1980); W. B. White, M. Ballow, N. Engl. J. Med. 312, 198 (1985). In vivo and in vitro effects on angiogenesis and tumor growth: T. Natori et al., Biomed. Pharmacother. 59, 56 (2005). Review of effect on endocrine secretion: C. Scarpignato, G. Bertaccini, Drugs Exp. Clin. Res. 5(4-5), 129-140 (1979). Symposium on clinical efficacy, cytoprotection and antifibrinolytic effects: Scand. J. Gastroenterol. 21, Suppl. 121, 1-62 (1986). Review of safety profile and drug interactions: A. F. Shinn, Drug Saf. 7, 245-267 (1992).

Properties

Derivative